Poly Medicure Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Poly Medicure's Q1 FY26 consolidated revenue grew 5% to Rs. 403 Cr, with PAT at Rs. 93 Cr. EBITDA margin was 26.3%. Domestic revenue jumped 20% to Rs. 126 Cr, maintaining a 30% FY26 growth outlook. International revenue saw a slight 1% dip to Rs. 275 Cr, impacted by European slowdown, leading to a revised 5-10% FY26 international growth outlook. Renal business soared 46%, and cardiology is gaining traction. Management remains confident in domestic market strength and new product pipeline, anticipating international business to rebound in H2.